In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

ConclusionsPremedication with Entresto® results in a relevant stabilization of [177Lu]Lu-PP-FF11N and consecutively increases radiation doses in tumors and organs.Trial registration clinicaltrails.gov, NCT03647657. Registered 20 August 2018.
Source: EJNMMI Research - Category: Radiology Source Type: research